Several studies have verified the availability of neoadjuvant-targeted therapy for NSCLC patients with ROS1, ALK, and epidermal growth factor receptor (EGFR) alterations (7–9); however, there are no reports regarding pralsetinib as neoadjuvant treatment for NSCLC patients with a RET rearrangement. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.